The FDA publicly promotes regulatory flexibility for rare diseases, yet industry insiders perceive it as less permissive than prior administrations. This disconnect between the agency's messaging and its actual decisions is fueling widespread criticism, investor uncertainty, and accusations of 'moving the goalposts'.

CellSci's drug trial ran into a stricter FDA under one administration after a period of more lenient approvals under the previous one. This political "pendulum swing" can derail promising drugs, showing that regulatory risk is not static but subject to unpredictable political change.

Despite the FDA leadership co-authoring an editorial supporting single-trial approvals, the industry is skeptical. The agency's recent inconsistent actions mean no executive or investor can confidently build a development strategy or financial model based on this policy, rendering the announcement largely ineffective.

The current unpredictability at the FDA is so pronounced that prominent biotech investor Peter Kolchinsky of RA Capital is now advising his portfolio companies to de-risk development by conducting early-stage clinical trials outside the United States. This marks a significant strategic shift for US-based innovators.

An ideologically driven and inconsistent FDA is eroding investor confidence, turning the U.S. into a difficult environment for investment in complex biologics like gene therapies and vaccines, potentially pushing innovation to other countries.

Unpredictable changes in FDA review processes are more destructive to biotech investment than consistently high approval standards. Investors can adapt to a stringent but stable regulatory bar, but constant changes undermine the multi-year planning and capital commitment required for drug development, causing investors to flee.

Moderna spent $1 billion on a trial based on FDA guidance that was later deemed unacceptable. This arbitrary "changing of the rules" after the fact makes long-term, capital-intensive investment in new medicines like vaccines extremely risky for pharmaceutical companies.

Investors perceive that the departure of CBER head Vinay Prasad could end a period of regulatory unpredictability. The hope is for a return to more stable, agreed-upon development pathways, which is a critical factor for de-risking investments in biotech companies.

Recent events, like Moderna's rescinded 'refusal to file' letter, reveal that alignment with FDA staff on trial design is no guarantee. Senior leaders, notably Vinay Prasad, are reportedly overturning prior agreements, creating extreme uncertainty and making it impossible for companies to trust the regulatory guidance they receive.